Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

DOI Full Paper Access

85

Citations

38

References

2020

Year

Markus Hecht, Antoniu‐Oreste Gostian, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias Hautmann, Günther Klautke, Simon Laban, Thomas Brunner,

Journal for ImmunoTherapy of Cancer

Abstract

Single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab is feasible and achieves a high biopsy-proven pCR rate.

References

	Year	Citations

Page 1